Revolution Medicines Statistics
Total Valuation
RVMD has a market cap or net worth of $40.67 billion. The enterprise value is $37.92 billion.
| Market Cap | 40.67B |
| Enterprise Value | 37.92B |
Important Dates
The next estimated earnings date is Wednesday, November 4, 2026, after market close.
| Earnings Date | Nov 4, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
RVMD has 214.34 million shares outstanding. The number of shares has increased by 10.45% in one year.
| Current Share Class | 214.34M |
| Shares Outstanding | 214.34M |
| Shares Change (YoY) | +10.45% |
| Shares Change (QoQ) | +6.46% |
| Owned by Insiders (%) | 2.17% |
| Owned by Institutions (%) | 89.10% |
| Float | 184.61M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 60.90 |
| PB Ratio | 15.60 |
| P/TBV Ratio | 16.04 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 11.38, with a Debt / Equity ratio of 0.46.
| Current Ratio | 11.38 |
| Quick Ratio | 11.12 |
| Debt / Equity | 0.46 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -27.42 |
Financial Efficiency
Return on equity (ROE) is -79.09% and return on invested capital (ROIC) is -33.68%.
| Return on Equity (ROE) | -79.09% |
| Return on Assets (ROA) | -30.12% |
| Return on Invested Capital (ROIC) | -33.68% |
| Return on Capital Employed (ROCE) | -41.00% |
| Weighted Average Cost of Capital (WACC) | 11.73% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$2.00M |
| Employee Count | 883 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +296.82% in the last 52 weeks. The beta is 1.40, so RVMD's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | +296.82% |
| 50-Day Moving Average | 203.43 |
| 200-Day Moving Average | 148.91 |
| Relative Strength Index (RSI) | 38.19 |
| Average Volume (20 Days) | 2,286,307 |
Short Selling Information
The latest short interest is 9.67 million, so 4.51% of the outstanding shares have been sold short.
| Short Interest | 9.67M |
| Short Previous Month | 9.73M |
| Short % of Shares Out | 4.51% |
| Short % of Float | 5.24% |
| Short Ratio (days to cover) | 5.53 |
Income Statement
| Revenue | n/a |
| Gross Profit | -1.30B |
| Operating Income | -1.63B |
| Pretax Income | -1.77B |
| Net Income | -1.77B |
| EBITDA | -1.62B |
| EBIT | -1.63B |
| Earnings Per Share (EPS) | -$8.92 |
Balance Sheet
The company has $3.94 billion in cash and $1.19 billion in debt, with a net cash position of $2.75 billion or $12.82 per share.
| Cash & Cash Equivalents | 3.94B |
| Total Debt | 1.19B |
| Net Cash | 2.75B |
| Net Cash Per Share | $12.82 |
| Equity (Book Value) | 2.61B |
| Book Value Per Share | 12.16 |
| Working Capital | 3.67B |
Cash Flow
In the last 12 months, operating cash flow was -$1.22 billion and capital expenditures -$9.10 million, giving a free cash flow of -$1.23 billion.
| Operating Cash Flow | -1.22B |
| Capital Expenditures | -9.10M |
| Depreciation & Amortization | 9.06M |
| Net Borrowing | 487.07M |
| Free Cash Flow | -1.23B |
| FCF Per Share | -$5.75 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
RVMD does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -10.45% |
| Shareholder Yield | -10.45% |
| Earnings Yield | -4.35% |
| FCF Yield | -3.03% |
Analyst Forecast
The average price target for RVMD is $259.14, which is 36.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $259.14 |
| Price Target Difference | 36.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 24 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |